CPC A61K 33/00 (2013.01) [A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 9/16 (2013.01); A61K 9/7023 (2013.01); A61K 31/045 (2013.01); A61K 31/133 (2013.01); A61K 31/198 (2013.01); A61K 31/4172 (2013.01); A61K 31/661 (2013.01); A61K 31/685 (2013.01); A61K 31/704 (2013.01); A61K 33/30 (2013.01); A61K 33/42 (2013.01); A61K 35/00 (2013.01); A61K 39/3955 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/14 (2013.01); A61K 47/183 (2013.01); A61K 47/22 (2013.01); A61K 47/24 (2013.01); A61P 35/04 (2018.01); C07K 16/2818 (2013.01); A61K 2039/505 (2013.01); C07K 2317/76 (2013.01)] | 20 Claims |
1. A method of treating a gout, comprising administering a transdermal formulation comprising a buffering agent, wherein the transdermal formulation comprising the buffering agent is administered to a patient having abnormal levels of uric acid crystals in one or more joints, tendons or surrounding tissue, and wherein the buffering agent reduces the levels of uric acid crystals in the one or more joints, tendons or surrounding tissue of said patient, resulting in a reduction in the symptoms of the a gout, wherein the buffering agent consists of sodium bicarbonate.
|